Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2025-12-28 @ 1:37 PM
Study NCT ID:
NCT00374868
Status:
COMPLETED
Last Update Posted:
2010-11-04
First Post:
2006-09-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)
Sponsor:
Eli Lilly and Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
8679
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Chief Medical Officer
Old Organization:
Eli Lilly